Cargando…

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition

BACKGROUND: Gastric cancer is the second leading cause of cancer mortality in the world. The receptor tyrosine kinase MET is constitutively activated in many gastric cancers and its expression is strictly required for survival of some gastric cancer cells. Thus, MET is considered a good candidate fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Corso, Simona, Ghiso, Elena, Cepero, Virna, Sierra, J Rafael, Migliore, Cristina, Bertotti, Andrea, Trusolino, Livio, Comoglio, Paolo M, Giordano, Silvia
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892452/ https://www.ncbi.nlm.nih.gov/pubmed/20500904 http://dx.doi.org/10.1186/1476-4598-9-121

Ejemplares similares

β4 integrin activates a Shp2–Src signaling pathway that sustains HGF-induced anchorage-independent growth
por: Bertotti, Andrea, et al.
Publicado: (2006)

The Met oncogene and basal-like breast cancer: another culprit to watch out for?
por: Gastaldi, Stefania, et al.
Publicado: (2010)

ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis
por: Lazzari, Luca, et al.
Publicado: (2013)

Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages
por: Sierra, Jose Rafael, et al.
Publicado: (2008)

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
por: Sierra, J Rafael, et al.
Publicado: (2010)

hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
por: Martinelli, Ilaria, et al.
Publicado: (2022)

Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
por: Martinelli, Ilaria, et al.
Publicado: (2022)

Activation of RAS family members confers resistance to ROS1 targeting drugs
por: Cargnelutti, Marilisa, et al.
Publicado: (2014)

Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals
por: Lupo, Barbara, et al.
Publicado: (2016)

An mTOR feedback loop mediates the ‘flare’ (‘rebound’) response to MET tyrosine kinase inhibition
por: Altintas, D. M., et al.
Publicado: (2023)

MET Oncogene Controls Invasive Growth by Coupling with NMDA Receptor
por: Gallo, Simona, et al.
Publicado: (2022)

C-met inhibition blocks bone metastasis development induced by renal cancer stem cells
por: D'Amico, Lucia, et al.
Publicado: (2016)

A diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells
por: Picco, Gabriele, et al.
Publicado: (2015)

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
por: Pietrantonio, Filippo, et al.
Publicado: (2023)

A Natural Hepatocyte Growth Factor/Scatter Factor Autocrine Loop in Myoblast Cells and the Effect of the Constitutive Met Kinase Activation on Myogenic Differentiation
por: Anastasi, Sergio, et al.
Publicado: (1997)

An Observatory for the MET Oncogene: A Guide for Targeted Therapies
por: Altintas, Dogus M., et al.
Publicado: (2023)

EGAsubmitter: A software to automate submission of nucleic acid sequencing data to the European Genome-phenome Archive
por: Viviani, Marco, et al.
Publicado: (2023)

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
por: Chiriaco, Cristina, et al.
Publicado: (2022)

Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation
por: Virzì, Anna Rita, et al.
Publicado: (2018)

MicroRNA 483‐3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis
por: Candiello, Ermes, et al.
Publicado: (2023)

HGF and MET: From Brain Development to Neurological Disorders
por: Desole, Claudia, et al.
Publicado: (2021)

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer
por: Puvanenthiran, Soozana, et al.
Publicado: (2018)

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
por: Ghiso, Elena, et al.
Publicado: (2017)

MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin
por: Stella, Giulia M., et al.
Publicado: (2017)

Discovery of molecular determinants of response to targeted therapies in colorectal cancer using patient-derived xenografts (‘xenopatients’)
por: Sassi, Francesco, et al.
Publicado: (2013)

miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
por: Migliore, Cristina, et al.
Publicado: (2018)

Targeted therapies for gastric cancer: failures and hopes from clinical trials
por: Apicella, Maria, et al.
Publicado: (2017)

Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody
por: Modica, Chiara, et al.
Publicado: (2020)

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
por: Belli, Valentina, et al.
Publicado: (2019)

Semaphorin 4D regulates gonadotropin hormone–releasing hormone-1 neuronal migration through PlexinB1–Met complex
por: Giacobini, Paolo, et al.
Publicado: (2008)

Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2023)

Prognostic significance of the expression of HER family members in primary osteosarcoma
por: Wang, Sheng-Lin, et al.
Publicado: (2018)

A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met
por: Basilico, Cristina, et al.
Publicado: (2008)

A receptor-antibody hybrid hampering MET-driven metastatic spread
por: Modica, Chiara, et al.
Publicado: (2021)

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
por: Martin, Valentina, et al.
Publicado: (2019)

Activation of the MET receptor attenuates doxorubicin‐induced cardiotoxicity in vivo and in vitro
por: Gallo, Simona, et al.
Publicado: (2020)

MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk
por: Modica, Chiara, et al.
Publicado: (2018)

Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity
por: Cascianelli, Silvia, et al.
Publicado: (2023)

Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors
por: Yıldız, Yetkin, et al.
Publicado: (2016)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gapgvi7u8cekshn8dmbgnb5isk